The FDA today warned Meridian Bioscience (NSDQ:VIVO) subsidiary Magellan Diagnostics based on the Class I recall of its lead poisoning tests, accusing the company of failing to protect patients after it learned of problems with the tests.
The May recall, which was expanded in July, involves Magellan’s LeadCare, LeadCare II, Ultra and Plus products. The tests may underestimate blood lead levels and provide inaccurate results with venous blood samples.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA warns Magellan Diagnostics on lead tests appeared first on MassDevice.
from MassDevice http://ift.tt/2gEv9vv
Cap comentari:
Publica un comentari a l'entrada